Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corvus Pharmaceuticals, Inc. - Common Stock (NQ:CRVS)

17.48 -0.61 (-3.34%)
Streaming Delayed Price Updated: 10:52 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corvus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad... 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 10, 2022 ↗
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
News headline image
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying ↗
The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More ↗
The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
News headline image
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
News headline image
Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Preview For Corvus Pharmaceuticals ↗
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022 ↗
Upgrades 
Via Benzinga
News headline image
10 Best Stocks to Buy Now According to Jeffrey Diehl’s Adams Street Partners ↗
In this article, we will be taking a look at some of the top stocks in the portfolio of Jeffrey Diehl. 
Via Talk Markets
News headline image
Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer ↗
 
Via Benzinga
News headline image
Corvus Pharmaceuticals: Q2 Earnings Insights ↗
  Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: Corvus Pharmaceuticals Q4 Earnings ↗
Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
A Preview Of Corvus Pharmaceuticals's Earnings ↗
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus... 
Via Benzinga
News headline image
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday ↗
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
News headline image
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday ↗
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers GBS (NASDAQ:GBS 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Ardelyx (NASDAQ:ARDX) stock increased by 19.29% to $1.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $153.3... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.